Phase 2 study of Renzapride in patients with diabetic gastroparesis

Trial Profile

Phase 2 study of Renzapride in patients with diabetic gastroparesis

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Renzapride (Primary)
  • Indications Diabetic gastroparesis
  • Focus Registrational; Therapeutic Use
  • Sponsors EndoLogic
  • Most Recent Events

    • 09 Aug 2017 According to an EndoLogic media release, company anticipate submitting the IND in the fourth quarter of 2017, with dosing of the first patient expected in the second quarter of 2018.
    • 09 Aug 2017 According to an EndoLogic media release, if successful, this study will be considered as one of two pivotal trials essential to submit an NDA.
    • 03 May 2017 According to an EndoLogic media release, the FDA has scheduled a pre-IND meeting with EndoLogic to discuss the requirements for this proposed phase II study. The meeting will be on July 25, 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top